NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free AVXL Stock Alerts $5.06 +0.22 (+4.55%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$4.80▼$5.1150-Day Range$4.55▼$6.7552-Week Range$4.48▼$10.45Volume932,823 shsAverage Volume1.50 million shsMarket Capitalization$415.48 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Anavex Life Sciences alerts: Email Address Anavex Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside690.5% Upside$40.00 Price TargetShort InterestBearish24.36% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.09Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.59 out of 5 starsMedical Sector280th out of 939 stocksBiological Products, Except Diagnostic Industry35th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Anavex Life Sciences has a forecasted upside of 690.5% from its current price of $5.06.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.36% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 0.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 1.7 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Anavex Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.60% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.55% of the stock of Anavex Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.63) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Anavex Life Sciences Stock (NASDAQ:AVXL)Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Read More AVXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Stock News HeadlinesMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXLMarch 27, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)March 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 27, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)March 27, 2024 | prnewswire.comContact Levi & Korsinsky by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL)March 26, 2024 | prnewswire.comInvestors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXLMarch 25, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) InvestorsMarch 25, 2024 | globenewswire.comAnavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 21, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) InvestorsMarch 21, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) InvestorsMarch 21, 2024 | businesswire.comAVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!March 21, 2024 | businesswire.comAVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!March 21, 2024 | prnewswire.comAVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!March 20, 2024 | stockhouse.comDEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming DeadlineMarch 20, 2024 | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Share Price Crosses Below 50-Day Moving Average of $5.69March 20, 2024 | prnewswire.comLost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXLMarch 19, 2024 | stockhouse.comSHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationMarch 19, 2024 | businesswire.comAVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 18, 2024 | businesswire.comAnavex Life Sciences Corporation Stockholder Alert: Robbins LLP Reminds Investors of AVXL Class ActionMarch 18, 2024 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in SchizophreniaMarch 18, 2024 | finance.yahoo.comAVXL Apr 2024 10.000 callMarch 18, 2024 | globenewswire.comAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in SchizophreniaMarch 17, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexMarch 15, 2024 | finance.yahoo.comAVXL Oct 2024 7.000 callMarch 15, 2024 | ca.finance.yahoo.comAVXL Mar 2024 5.500 callSee More Headlines Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+690.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.32% Return on Assets-27.87% Debt Debt-to-Equity RatioN/A Current Ratio11.85 Quick Ratio11.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book2.92Miscellaneous Outstanding Shares82,110,000Free Float72,588,000Market Cap$415.48 million OptionableOptionable Beta0.58 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Christopher U. Missling M.B.A. (Age 58)M.S., Ph.D., President, CEO, Secretary & Director Comp: $828.25kMs. Sandra Boenisch CPA (Age 43)CGA, Principal Financial Officer & Treasurer Comp: $194.36kMr. Stephan Toutain M.B.A. (Age 58)M.S., Senior VP of Operations & COO Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerClint TomlinsonVP of CorporateDr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentDr. Edward R Hammond M.D.M.P.H., Ph.D., Chief Medical OfficerDr. Kun Jin Ph.D.Head of BiostatisticsMr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsMesoblastNASDAQ:MESOMeiraGTxNASDAQ:MGTXLexeo TherapeuticsNASDAQ:LXEOInvivydNASDAQ:IVVDTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 115,304 shares on 3/11/2024Ownership: 5.311%Goldman Sachs Group Inc.Bought 45,556 shares on 3/1/2024Ownership: 0.325%Virtu Financial LLCBought 21,658 shares on 2/26/2024Ownership: 0.026%Profund Advisors LLCSold 7,595 shares on 2/15/2024Ownership: 0.047%Wolverine Trading LLCBought 13,500 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AVXL Stock Analysis - Frequently Asked Questions Should I buy or sell Anavex Life Sciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares. View AVXL analyst ratings or view top-rated stocks. What is Anavex Life Sciences' stock price target for 2024? 1 Wall Street analysts have issued 1 year price objectives for Anavex Life Sciences' shares. Their AVXL share price targets range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 690.5% from the stock's current price. View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts. How have AVXL shares performed in 2024? Anavex Life Sciences' stock was trading at $9.31 at the start of the year. Since then, AVXL stock has decreased by 45.6% and is now trading at $5.06. View the best growth stocks for 2024 here. When is Anavex Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AVXL earnings forecast. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. What ETF holds Anavex Life Sciences' stock? iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.31%), Vanguard Group Inc. (5.31%), DLD Asset Management LP (0.00%), Nwam LLC (0.97%), Northern Trust Corp (0.90%) and Charles Schwab Investment Management Inc. (0.76%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVXL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.